BACKGROUND: Several observational studies have shown decreases in measured influenza vaccine effectiveness (mVE) during influenza seasons. One study found decreases of 6-11%/month during the 2011-2012 to 2014-2015 seasons. These findings could indicate waning immunity but could also occur if vaccine effectiveness is stable and vaccine provides partial protection in all vaccinees ("leaky") rather than complete protection in a subset of vaccinees. Since it is unknown whether influenza vaccine is leaky, we simulated the 2011-2012 to 2014-2015 influenza seasons to estimate the potential contribution of leaky vaccine effect to the observed decline in mVE. METHODS: We used available data to estimate daily numbers of vaccinations and infections with A/H1N1, A/H3N2, and B viruses. We assumed that vaccine effect was leaky, calculated mVE as 1 minus the Mantel-Haenszel relative risk of vaccine on incident cases, and determined the mean mVE change per 30 days since vaccination. Because change in mVE was highly dependent on infection rates, we performed simulations using low (15%) and high (31%) total (including symptomatic and asymptomatic) seasonal infection rates. RESULTS: For the low infection rate, decreases (absolute) in mVE per 30 days after vaccination were 2% for A/H1N1 and 1% for A/H3N2and B viruses. For the high infection rate, decreases were 5% for A/H1N1, 4% for A/H3, and 3% for B viruses. CONCLUSIONS: The leaky vaccine bias could account for some, but probably not all, of the observed intraseasonal decreases in mVE. These results underscore the need for strategies to deal with intraseasonal vaccine effectiveness decline. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Several observational studies have shown decreases in measured influenza vaccine effectiveness (mVE) during influenza seasons. One study found decreases of 6-11%/month during the 2011-2012 to 2014-2015 seasons. These findings could indicate waning immunity but could also occur if vaccine effectiveness is stable and vaccine provides partial protection in all vaccinees ("leaky") rather than complete protection in a subset of vaccinees. Since it is unknown whether influenza vaccine is leaky, we simulated the 2011-2012 to 2014-2015 influenza seasons to estimate the potential contribution of leaky vaccine effect to the observed decline in mVE. METHODS: We used available data to estimate daily numbers of vaccinations and infections with A/H1N1, A/H3N2, and B viruses. We assumed that vaccine effect was leaky, calculated mVE as 1 minus the Mantel-Haenszel relative risk of vaccine on incident cases, and determined the mean mVE change per 30 days since vaccination. Because change in mVE was highly dependent on infection rates, we performed simulations using low (15%) and high (31%) total (including symptomatic and asymptomatic) seasonal infection rates. RESULTS: For the low infection rate, decreases (absolute) in mVE per 30 days after vaccination were 2% for A/H1N1 and 1% for A/H3N2and B viruses. For the high infection rate, decreases were 5% for A/H1N1, 4% for A/H3, and 3% for B viruses. CONCLUSIONS: The leaky vaccine bias could account for some, but probably not all, of the observed intraseasonal decreases in mVE. These results underscore the need for strategies to deal with intraseasonal vaccine effectiveness decline. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: G Thomas Ray; Ned Lewis; Nicola P Klein; Matthew F Daley; Marc Lipsitch; Bruce Fireman Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Barnaby Young; Xiahong Zhao; Alex R Cook; Christopher M Parry; Annelies Wilder-Smith; Mark Chen I-Cheng Journal: Vaccine Date: 2016-12-07 Impact factor: 3.641
Authors: Huong Q McLean; Mark G Thompson; Maria E Sundaram; Burney A Kieke; Manjusha Gaglani; Kempapura Murthy; Pedro A Piedra; Richard K Zimmerman; Mary Patricia Nowalk; Jonathan M Raviotta; Michael L Jackson; Lisa Jackson; Suzanne E Ohmit; Joshua G Petrie; Arnold S Monto; Jennifer K Meece; Swathi N Thaker; Jessie R Clippard; Sarah M Spencer; Alicia M Fry; Edward A Belongia Journal: J Infect Dis Date: 2014-11-18 Impact factor: 5.226
Authors: Q Sue Huang; Don Bandaranayake; Tim Wood; E Claire Newbern; Ruth Seeds; Jacqui Ralston; Ben Waite; Ange Bissielo; Namrata Prasad; Angela Todd; Lauren Jelley; Wendy Gunn; Anne McNicholas; Thomas Metz; Shirley Lawrence; Emma Collis; Amanda Retter; Sook-San Wong; Richard Webby; Judy Bocacao; Jennifer Haubrock; Graham Mackereth; Nikki Turner; Barbara McArdle; John Cameron; Edwin G Reynolds; Michael G Baker; Cameron C Grant; Colin McArthur; Sally Roberts; Adrian Trenholme; Conroy Wong; Susan Taylor; Paul Thomas; Jazmin Duque; Diane Gross; Mark G Thompson; Marc-Alain Widdowson Journal: J Infect Dis Date: 2019-01-09 Impact factor: 5.226
Authors: Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Arnold S Monto; Donald Middleton; Fernanda Silveira; H Keipp Talbot; Richard Zimmerman; Manish Patel Journal: Clin Infect Dis Date: 2021-08-16 Impact factor: 9.079